G207 Orphan Designation

Treovir announces that G207 has been awarded Orphan Drug designation by the US FDA for treatment of medulloblastoma (DRU-2019-824) and primitive neuroectodermal brain tumor (PNET) (DRU-2019-6922). Together with the previous orphan designation in glioblastoma (2002-1552), Treovir will use these orphan designations to ensure development of G207 in multiple brain tumor indications.